Skip to main content
Erschienen in: Journal of Neurology 5/2012

01.05.2012 | Original Communication

Transcranial sonography in pantothenate kinase-associated neurodegeneration

verfasst von: Vladimir S. Kostić, Marina Svetel, Milija Mijajlović, Aleksandra Pavlović, Milica Ječmenica-Lukić, Dušan Kozić

Erschienen in: Journal of Neurology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

After it was reported that increased tissue iron concentrations were associated with increased echogenicity of the substantia nigra (SN) obtained with transcranial sonography (TCS) in animal and postmortem studies, our goal was to use this method in a disorder characterized with iron accumulation in human brain tissue. Therefore, magnetic resonance imaging (MRI) and TCS were conducted in 5 unrelated patients with pantothenate kinase-associated neurodegeneration (PKAN), caused by PANK2 mutations. All patients had an eye of the tiger sign. Hypointense lesions on the T2-weighted MRI images were restricted to the globus pallidus (GP) and SN. TCS also revealed bilateral hyperechogenicity restricted to the LN and SN, with normal DTV values. Both TCS and MRI studies in PKAN patients are in accordance with the pathological findings that accumulation of iron, even in advanced cases, is restricted to the GP and SN, suggesting selective involvement of these structures.
Literatur
1.
Zurück zum Zitat Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinsonʼs disease visualized by transcranial color-coded real-time sonography. Neurology 45:182–184PubMedCrossRef Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinsonʼs disease visualized by transcranial color-coded real-time sonography. Neurology 45:182–184PubMedCrossRef
2.
Zurück zum Zitat Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinsonʼs disease and its relation to clinical findings. J Neurol 248:684–689PubMedCrossRef Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinsonʼs disease and its relation to clinical findings. J Neurol 248:684–689PubMedCrossRef
3.
Zurück zum Zitat Walter U, Wittstock M, Benecke R, Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinsonʼs disease. J Neural Transm 109:191–196PubMedCrossRef Walter U, Wittstock M, Benecke R, Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinsonʼs disease. J Neural Transm 109:191–196PubMedCrossRef
4.
Zurück zum Zitat Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1053PubMedCrossRef Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1053PubMedCrossRef
5.
Zurück zum Zitat Skoloudík D, Walter U (2010) Method and validity of transcranial sonography in movement disorders. Int Rev Neurobiol 90:7–34PubMedCrossRef Skoloudík D, Walter U (2010) Method and validity of transcranial sonography in movement disorders. Int Rev Neurobiol 90:7–34PubMedCrossRef
6.
Zurück zum Zitat Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031PubMedCrossRef Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031PubMedCrossRef
7.
Zurück zum Zitat Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005PubMedCrossRef Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005PubMedCrossRef
8.
Zurück zum Zitat Hochstrasser H, Bauer P, Walter U et al (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63:1912–1917PubMedCrossRef Hochstrasser H, Bauer P, Walter U et al (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63:1912–1917PubMedCrossRef
9.
Zurück zum Zitat Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinsonʼs disease—ultrasonography as a biomarker. Neurotoxic Res 9:1–13CrossRef Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinsonʼs disease—ultrasonography as a biomarker. Neurotoxic Res 9:1–13CrossRef
10.
Zurück zum Zitat Berg D, Godau J, Riederer P, Gerlach M, Arzbetrger T (2010) Microglia activation is related to substantia nigra echogenicity. J Neural Transm 117:1287–1292PubMedCrossRef Berg D, Godau J, Riederer P, Gerlach M, Arzbetrger T (2010) Microglia activation is related to substantia nigra echogenicity. J Neural Transm 117:1287–1292PubMedCrossRef
11.
Zurück zum Zitat Hayflick SJ, Westaway SK, Levinson B et al (2003) Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 348:33–40PubMedCrossRef Hayflick SJ, Westaway SK, Levinson B et al (2003) Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 348:33–40PubMedCrossRef
12.
Zurück zum Zitat Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28:345–349PubMedCrossRef Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28:345–349PubMedCrossRef
13.
Zurück zum Zitat Hartig MB, Hortnagel K, Garavaglia B et al (2006) Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 59:248–256PubMedCrossRef Hartig MB, Hortnagel K, Garavaglia B et al (2006) Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 59:248–256PubMedCrossRef
14.
Zurück zum Zitat Mijajlović M, Petrović I, Stojković T, Svetel M, Stefanova E, Kostić VS (2008) Transcranial parenchymal sonography in Parkinson’s disease. Vojnosanit Pregl 65:601–605PubMedCrossRef Mijajlović M, Petrović I, Stojković T, Svetel M, Stefanova E, Kostić VS (2008) Transcranial parenchymal sonography in Parkinson’s disease. Vojnosanit Pregl 65:601–605PubMedCrossRef
16.
Zurück zum Zitat Gregory A, Hayflick SJ (2005) Neurodegeneration with brain iron accumulation. Folia Neuropathol 43:286–296PubMed Gregory A, Hayflick SJ (2005) Neurodegeneration with brain iron accumulation. Folia Neuropathol 43:286–296PubMed
17.
Zurück zum Zitat Berg D, Grote C, Rausch WD et al (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901–904PubMedCrossRef Berg D, Grote C, Rausch WD et al (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901–904PubMedCrossRef
18.
Zurück zum Zitat Zecca L, Berg D, Arzberger T et al (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278–1285PubMedCrossRef Zecca L, Berg D, Arzberger T et al (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278–1285PubMedCrossRef
19.
Zurück zum Zitat Spatz H (1922) Uber des Eisenmachweiss im Gehirn besonders in Zentren des extra-pyramidalmotorischen Systems. Z Gesamte Neurol Psychiatr 77:261CrossRef Spatz H (1922) Uber des Eisenmachweiss im Gehirn besonders in Zentren des extra-pyramidalmotorischen Systems. Z Gesamte Neurol Psychiatr 77:261CrossRef
20.
Zurück zum Zitat Swaiman KF (1991) Hallervorden-Spatz syndrome and iron brain metabolism. Arch Neurol 48:1285–1293PubMedCrossRef Swaiman KF (1991) Hallervorden-Spatz syndrome and iron brain metabolism. Arch Neurol 48:1285–1293PubMedCrossRef
21.
Zurück zum Zitat Schneider SA, Hardy J, Bhatia KP (2009) Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? J Neurol Neurosurg Psychiatry 80:589–590PubMedCrossRef Schneider SA, Hardy J, Bhatia KP (2009) Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: causative or consequential? J Neurol Neurosurg Psychiatry 80:589–590PubMedCrossRef
22.
Zurück zum Zitat Koeppen AH, Dickson AC (2001) Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 25:148–155PubMedCrossRef Koeppen AH, Dickson AC (2001) Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 25:148–155PubMedCrossRef
23.
Zurück zum Zitat Mutoh K, Okuno T, Ito M et al (1988) MR imaging of a group I case of Hallervorden-Spatz disease. J Comput Assist Tomogr 12:851–853PubMedCrossRef Mutoh K, Okuno T, Ito M et al (1988) MR imaging of a group I case of Hallervorden-Spatz disease. J Comput Assist Tomogr 12:851–853PubMedCrossRef
24.
Zurück zum Zitat Sethi KD, Adams RJ, Loring DW, Gammal T (1988) Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 24:692–694PubMedCrossRef Sethi KD, Adams RJ, Loring DW, Gammal T (1988) Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 24:692–694PubMedCrossRef
25.
Zurück zum Zitat McNeill A, Birchall D, Hayflick SJ et al (2008) T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 70:1614–1619PubMedCrossRef McNeill A, Birchall D, Hayflick SJ et al (2008) T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 70:1614–1619PubMedCrossRef
26.
Zurück zum Zitat Lee JH, Kim DS, Baik SK, Nam SO (2010) Nigropallidal iron accumulation in pantothenate kinase-associated neurodegeneration demonstrated by susceptibility-weighted imaging. J Neurol 257:661–662PubMedCrossRef Lee JH, Kim DS, Baik SK, Nam SO (2010) Nigropallidal iron accumulation in pantothenate kinase-associated neurodegeneration demonstrated by susceptibility-weighted imaging. J Neurol 257:661–662PubMedCrossRef
27.
Zurück zum Zitat Hayflick SJ, Penzien JM, Michi W, Sharif UM, Rosman NP, Wheeler PG (2001) Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 25:166–169PubMedCrossRef Hayflick SJ, Penzien JM, Michi W, Sharif UM, Rosman NP, Wheeler PG (2001) Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 25:166–169PubMedCrossRef
28.
Zurück zum Zitat Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H (2006) Brain MRI in Neurodegeneration with brain iron accumulation with and without PANK2 mutations. Am J Neuroradiol 27:1230–1233PubMed Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H (2006) Brain MRI in Neurodegeneration with brain iron accumulation with and without PANK2 mutations. Am J Neuroradiol 27:1230–1233PubMed
29.
Zurück zum Zitat Bruggemann N, Hagenah J, Reetz K et al (2010) Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging data. Arch Neurol 67:1357–1363PubMedCrossRef Bruggemann N, Hagenah J, Reetz K et al (2010) Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging data. Arch Neurol 67:1357–1363PubMedCrossRef
30.
Zurück zum Zitat Liman J, Wellmer A, Rostasy K, Bahr M, Kermer P (2011) Transcranial ultrasound in neurodegeneration with brain iron accumulation (NBIA). Eur J Paediatr Neurol. doi:10.1016/ejpn.2011.07.009 Liman J, Wellmer A, Rostasy K, Bahr M, Kermer P (2011) Transcranial ultrasound in neurodegeneration with brain iron accumulation (NBIA). Eur J Paediatr Neurol. doi:10.​1016/​ejpn.​2011.​07.​009
Metadaten
Titel
Transcranial sonography in pantothenate kinase-associated neurodegeneration
verfasst von
Vladimir S. Kostić
Marina Svetel
Milija Mijajlović
Aleksandra Pavlović
Milica Ječmenica-Lukić
Dušan Kozić
Publikationsdatum
01.05.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 5/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6294-4

Weitere Artikel der Ausgabe 5/2012

Journal of Neurology 5/2012 Zur Ausgabe

Pioneers in Neurology

Rhazes (865–925 AD)

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.